<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>By</th>
<th>Institutes</th>
</tr>
</thead>
<tbody>
<tr>
<td>418</td>
<td>Immunotherapy to treat bladder painful syndrome</td>
<td>Augé C.², Lluel P.², Vergnolle N.¹, Dietrich G.¹</td>
<td>Purpan Hospital, Inserm Umr1043, Toulouse, France, UROsphere, Dept. of Pharmacology, Toulouse, France</td>
</tr>
<tr>
<td>419</td>
<td>Toll like receptor 7 is overexpressed in the bladder mucosa of Hunner type interstitial cystitis and its activation in the mouse bladder induces cystitis and pain</td>
<td>Ichihara K.¹, Aizawa N.¹, Sugiyama R.¹, Ito H.¹, Kamei J.¹, Akiyama Y.¹, Masumori N.², Andersson K-E.⁴, Homma Y.³, Igawa Y.¹</td>
<td>The University of Tokyo Graduate School of Medicine, Dept. of Continence Medicine, Tokyo, Japan, Sapporo Medical University School of Medicine, Dept. of Urology, Sapporo, Japan, The University of Tokyo Graduate School of Medicine, Dept. of Urology, Tokyo, Japan, Aarhus University, Aarhus Institute of Advanced Studies, Aarhus, Denmark</td>
</tr>
<tr>
<td>420</td>
<td>Development and validation of a clinically-relevant chronic model of interstitial cystitis/bladder painful syndrome</td>
<td>Chabot S.¹, Augé C.¹, Meen M.¹, Guilloteau V.¹, Vergnolle N.², Gamé X.³, Lluel P.¹</td>
<td>Urosphere, Dept. of Urology, Toulouse, France, INSERM UMR1043, Purpan University Hospital, Toulouse, France, INSERM I2MC-U1048, Rangueil University Hospital, Dept. of Urology, Toulouse, France</td>
</tr>
<tr>
<td>421</td>
<td>Comparison of Cystistat®, iAluril®, and Whitmore Cocktail for treatment of patients with bladder pain syndrome/interstitial cystitis</td>
<td>Cocci A.¹, Alowidah I.², Skews R.², Hashim H.²</td>
<td>University of Florence, Dept. of Urology, Florence, Italy, Bristol Urological Institute, Dept. of Urology, Bristol, United Kingdom</td>
</tr>
<tr>
<td>422</td>
<td>Pelvic inflammatory disease is associated with bladder pain syndrome/interstitial cystitis: A population-based case-control study</td>
<td>Tan J-S.</td>
<td>Far Eastern Memorial Hospital, Dept. of Urology, New Taipei City, Taiwan</td>
</tr>
</tbody>
</table>
| 423     | The effect of intravesical liposome-based NGF antisense therapy on bladder overactivity and nociception in a rat model of cystitis induced by hydrogen peroxide | Majima T.¹, Tyagi P.², Dogishi K.³, Kashyap M.², Gotoh M.², Chancellor M.B.⁴, Yoshimura N.² | Nagoya University School of Medicine, Dept. of Urology, Nagoya, Japan, University of Pittsburgh, Dept. of Urology, Pittsburgh, United States of America, University of Kyoto, Dept. of Molecular Pharmacology, Kyoto, Japan, Oakland University William Beaumont School of
**Poster Session 34**

**Medicine, Dept. of Urology, Royal Oak, United States of America**

*424*  
**Chronic pelvic pain syndrome is similar as features and symptoms of occlusive lesions of common and internal iliac arteries**  
By: Belousov I., Kogan M.I.  
Institutes: Rostov State Medical University, Dept. of Urology, Rostov on Don, Russia

*425*  
**Analysis of multiple urine markers for the detection of interstitial cystitis/bladder pain syndrome in patients with lower urinary tract symptoms**  
By: Furuta A.¹, Yamamoto T.², Koike Y.¹, Suzuki Y.³, Goto M.², Egawa S.⁴, Yoshimura N.⁵  
Institutes: ¹Jikei University School Of Medicine, Dept. of Urology, Tokyo, Japan, ²Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan, ³Tokyo Metropolitan Rehabilitation Hospital, Dept. of Urology, Tokyo, Japan, ⁴Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ⁵University of Pittsburgh School of Medicine, Dept. of Urology, Pennsylvania, United States of America

*426*  
**Possible role of matrix metalloproteinase-8 in pathophysiology of interstitial cystitis/painful bladder syndrome**  
By: Piecha T.¹, Poletajew S.¹, Wyczka-Tomasik A.², Gala K.², Burdzińska A.², Pączek L.², Radziszewski P.¹  
Institutes: ¹Medical University of Warsaw, Dept. of General, Oncological and Functional Urology, Warsaw, Poland, ²Medical University of Warsaw, Dept. of Immunology, Transplantation and Internal Diseases, Warsaw, Poland

*427*  
**Plasma and urinary pharmacokinetics of the novel, oral SHIP1 activator, AQX-1125 in interstitial cystitis/bladder pain syndrome (IC/BPS): Results of the phase2 LEADERSHIP trial**  
By: Nickel C.², Evans R.³, Tam P.⁴, Toews J.⁴, MacKenzie L.⁴, Biagi H.¹, Shrewsbury S.¹  
Institutes: ¹Aquinox Pharmaceuticals, Dept. of Clinical Development, Vancouver, Canada, ²Queen’s University, Dept. of Urology, Kingston, Canada, ³Wake Forest University Health Sciences, Dept. of Urology, Winston Salem, United States of America, ⁴Aquinox Pharmaceuticals, Dept. of Technical Operations, Vancouver, Canada

*429*  
**5-HT in the rat prefrontal cortex controls the micturition reflex via 5-HT2A and 5-HT7**  
By: Hiroki C.¹, Mitsui T.², Kitta T.¹, Ohmura Y.³, Moriya K.¹, Kanno Y.¹, Yoshioka M.³, Shinohara N.¹  
Institutes: ¹Hokkaido University, Dept. of Urology, Sapporo, Japan, ²Yamanashi University, Dept. of Urology, Yamanashi, Japan, ³Hokkaido University, Dept. of Neuropharmacology, Sapporo, Japan

13:30 - 13:37  
**Summary and context**  
P. Dinis Oliveira, Porto (PT)